{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-015213","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.344727+00:00","generated_at":"2026-06-06T02:15:37.506021+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kintara Q2 net loss $1.0M; starts REM-001 CMBC study, explores strategic alternatives","bullets":["Q2 net loss $1.0M ($0.24/share) vs $3.5M ($2.10/share) year earlier; R&D fell to $0.1M from $2.1M.","Cash $0.7M at Dec 31, 2023; raised $6.1M net via ATM from Jan 1-Feb 12, 2024.","Initiated 15-patient REM-001 study in cutaneous metastatic breast cancer; costs covered by $2.0M SBIR grant from NIH.","Board reviewing strategic alternatives to maximize stockholder value; Ladenburg Thalmann engaged as financial advisor (Dec 2023).","VAL-083 development terminated after failure in GBM AGILE study (Oct 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-015213","json":"https://secwatch.observer/filing/0000950170-24-015213.json","markdown":"https://secwatch.observer/filing/0000950170-24-015213.md","text":"https://secwatch.observer/filing/0000950170-24-015213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/0000950170-24-015213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/ktra-20240214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:15:37.506021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c0ef37c00e1c9209e3844b536be591cbdc3d87d","claim":"TuHURA Biosciences, Inc./NV reported fiscal 2024 second quarter ended December 31, 2023 results: net income $1.0 million, EPS $0.24 per share.","evidence_excerpt":"For the three months ended December 31, 2023, Kintara reported a net loss of approximately $1.0 million, or $0.24 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/0000950170-24-015213-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 second quarter ended December 31, 2023"},{"label":"Net income","value":"$1.0 million"},{"label":"EPS","value":"$0.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}